Exploiting this concept, ATR inhibitors (ATRi) are in clinical development for the treatment of cancers (12) including those with mutations in the related kinase ataxia telangiectasia mutated (ATM) (13–16), or high endogenous replication stress (17–20). The gene discussed is ATM; the disease is cancer.